Mycostatin (Nystatin)

Nystatin binds to ergosterol, a sterol unique to fungal cell membranes. This binding creates pores that increase membrane permeability, causing leakage of essential intracellular components and leading to fungal cell death while sparing human cells that lack ergosterol.

The exact dose of Mycostatin is determined by the prescribing clinician based on the type and severity of the Candida infection, patient age, weight, and renal or hepatic function. Typical regimens vary, and the prescriber will provide specific dosing instructions tailored to the individual.

Safety data for Nystatin in pregnancy and lactation are limited. It is generally considered low risk because of minimal systemic absorption, but clinicians should evaluate the potential benefits against any possible risks and discuss options with the patient before prescribing.

To order Mycostatin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mycostatin (nystatin) is a polyene antifungal that acts locally in the gastrointestinal tract and has minimal systemic absorption, making it suitable for mucosal Candida infections. Azole agents (e.g., fluconazole) are systemically absorbed and used for deeper or invasive infections, but may have more drug‑drug interactions and resistance concerns.

Store Mycostatin at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Mycostatin is taken orally, usually as a suspension or tablet, as directed by the prescriber. It should be swallowed with water or mixed with a suitable vehicle if a suspension, and the full course should be completed even if symptoms improve early.

Serious adverse reactions, though rare, include severe allergic responses such as anaphylaxis, hepatic dysfunction, marked neutropenia, Stevens‑Johnson syndrome, and extensive mucosal ulceration. Patients should seek immediate medical attention if they experience signs of a severe reaction.

Mycostatin is contraindicated in individuals with a known hypersensitivity to nystatin or any component of the formulation. Caution is also advised for patients with severe renal impairment, active liver disease, or those receiving live oral vaccines, as these conditions may increase risk of adverse effects.